Device Trial Radar · NCT05221333
Sorrel 25R Injector - Sorrel Clinical Study Protocol
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 23, 2021
Primary completion
Dec 15, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Eitan MedicalNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Thomas Jefferson University
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
Conditions
- Injection Site
- Injection Site Reaction
- Injection Site Irritation
Interventions
Sorrel Wearable InjectorDevice
Use of Sorrel Wearable Injector in pilot study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reliability of SWITime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.